Amgen terminates rocatinlimab collaboration with Kyowa Kirin, effective upon HSR clearance

AMGEN INC

Termination agreement signed Jan 30, 2026 for 2021 License and Collaboration Agreement on rocatinlimab (KHK4083/AMG 451).
Amgen discontinuing participation; Kyowa Kirin to assume all development, manufacturing, and commercialization worldwide.
Transition effective upon satisfaction of HSR Act waiting period and other regulatory conditions.
If conditions not met by April 1, 2026 (extendable to June 1, 2026 due to government shutdown), Amgen may terminate and wind down.
Amgen and Kyowa Kirin also entering a Transition Agreement to facilitate transfer of activities.

item 1.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.